My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

60.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Host Investor Day on September 7, 2023
From Guardant Health, Inc.
Via Business Wire
The Latest Analyst Ratings for Guardant Health
 
Via Benzinga
Preview: Guardant Health's Earnings
 
Via Benzinga
Analyst Ratings for Guardant Health
 
Via Benzinga
2 Cathie Wood Stocks to Buy and Hold for 10 Years
These companies' growth stories still have plenty of exciting chapters ahead. 
Via The Motley Fool
Guardant Health Stock Sees Renewed Technical Strength
Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85. 
Via Investor's Business Daily
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
From Guardant Health, Inc.
Via Business Wire
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
From Guardant Health, Inc.
Via Business Wire
Why Shares of Guardant Health Jumped This Week
The cancer diagnostic company saw its shares take a big jump for the second straight week. 
Via The Motley Fool
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
From Guardant Health, Inc.
Via Business Wire
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
From Guardant Health, Inc.
Via Business Wire
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
From Guardant Health, Inc.
Via Business Wire
What 11 Analyst Ratings Have To Say About Guardant Health
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023
 
Via Benzinga
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Shares Move Lower On $350M Public Offering: The Details
Guardant Health Inc (NASDAQ: GH) shares are trading lower Tuesday after the company announced an offering.  
Via Benzinga
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Proposed Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
Guardant Health Releases Inaugural ESG Report
From Guardant Health, Inc.
Via Business Wire
Why Guardant Health's Shares Climbed This Week
The company, which focuses on oncology screenings, saw a big gain in revenue in the first quarter. 
Via The Motley Fool
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Guardant Health Reports First Quarter 2023 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Additions to Leadership Team
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.